Pipradrol: Difference between revisions
m Robot: Automated text replacement (-{{reflist}} +{{reflist|2}}, -<references /> +{{reflist|2}}, -{{WikiDoc Cardiology Network Infobox}} +) |
Rabin Bista (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
{{Drugbox | {{Drugbox | ||
|IUPAC_name = α,α-Diphenyl-2-piperidinemethanol | |IUPAC_name = α,α-Diphenyl-2-piperidinemethanol | ||
| image= | | image= Pipradol Wiki Str.png | ||
| width= 200px | | width= 200px | ||
| CAS_number= 46-76-07 | | CAS_number= 46-76-07 | ||
| Line 19: | Line 19: | ||
| routes_of_administration= | | routes_of_administration= | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}} | |||
== Overview == | |||
'''Pipradrol''' (Meretran) is a mild central nervous system [[stimulant]] that is no longer widely used in most countries due to concerns about its abuse potential, although this is less of a problem than with other stimulants that still are in current use such as [[methylphenidate]]. Pipradrol is still used in some European countries, and even rarely in the USA.<ref> http://www.biam2.org/www/Sub2393.html </ref> | '''Pipradrol''' (Meretran) is a mild central nervous system [[stimulant]] that is no longer widely used in most countries due to concerns about its abuse potential, although this is less of a problem than with other stimulants that still are in current use such as [[methylphenidate]]. Pipradrol is still used in some European countries, and even rarely in the USA.<ref> http://www.biam2.org/www/Sub2393.html </ref> | ||
| Line 35: | Line 38: | ||
{{stimulants}} | {{stimulants}} | ||
{{Psychostimulants, agents used for ADHD and nootropics}} | {{Psychostimulants, agents used for ADHD and nootropics}} | ||
[[Category:Drug]] | |||
[[Category:Stimulants]] | [[Category:Stimulants]] | ||
[[Category:Piperidines]] | [[Category:Piperidines]] | ||
Revision as of 13:42, 13 April 2015
 | |
| Clinical data | |
|---|---|
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C18H21NO |
| Molar mass | 267.37 |
|
WikiDoc Resources for Pipradrol |
|
Articles |
|---|
|
Most recent articles on Pipradrol |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Pipradrol at Clinical Trials.gov Clinical Trials on Pipradrol at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Pipradrol
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Pipradrol Discussion groups on Pipradrol Directions to Hospitals Treating Pipradrol Risk calculators and risk factors for Pipradrol
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Pipradrol |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Pipradrol (Meretran) is a mild central nervous system stimulant that is no longer widely used in most countries due to concerns about its abuse potential, although this is less of a problem than with other stimulants that still are in current use such as methylphenidate. Pipradrol is still used in some European countries, and even rarely in the USA.[1]
Pipradrol was developed in the 1950s and found use initially for treating obesity.[2] It was subsequently used for the treatment of a variety of other conditions such as narcolepsy, ADHD, and most particularly for counteracting the symptoms of senile dementia, this being the only application for which it is still used medically. Pipradrol proved useful for these applications as its relatively mild stimulant effects gave it a good safety profile compared to stronger stimulants. It was also trialled as an adjutant treatment for depression and schizophrenia although it was never widely used for these purposes.
Pipradrol was made illegal in many countries in the late 1970s, at the same time as many other drugs which had a history of abuse. The relatively mild stimulant effects of pipradrol meant that it was scheduled under the less restrictive classes in most countries (i.e. Class C in United Kingdom and New Zealand) but was still considered of sufficient abuse potential to be made an illegal drug. It is now an obscure compound that is virtually unknown as an illicit drug of abuse, but is still used for some scientific research, often as a comparison drug for testing other stimulants against.
Dosage is between 0.5 and 4 milligrams per day, typically taken as a single dose in the morning as the long duration of effects of pipradrol (up to 12 hours) means insomnia can be a problem especially if it is used at higher doses or taken too late in the day.
Common side effects include insomnia, anorexia, tachycardia, anxiety. Rarer side effects include dry mouth, tremor, hypertension, euphoria, depression, and very rarely psychosis or convulsions.
References
- ↑ http://www.biam2.org/www/Sub2393.html
- ↑ Gelvin EP, McGavack TH, Kenigsberg S. Alpha-(2-piperidyl) benzhydrol hydrochloride (pipradrol) as an adjunct in the dietary management of obesity. N Y State J Med. 1955 Aug 15;55(16):2336-8.
Template:Stimulants Template:Psychostimulants, agents used for ADHD and nootropics
- Pages with script errors
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Drug
- Stimulants
- Piperidines